Centessa Pharmaceuticals (CNTA) News Today

$5.92

-0.08 (-1.33%)

(As of 11/29/2023 ET)

Today's Range: $5.90
▼
$6.37
50-Day Range: $5.52
▼
$7.35
52-Week Range: $3.00
▼
$8.65

Volume: 344,807 shs
Average Volume: 133,568 shs
Market Capitalization: $577.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.43

Source

Source	Headline
	Centessa Pharmaceuticals plc - ADR (CNTA) Price Target Increased by 14.58% to 11.22 msn.com - November 27 at 3:05 PM
	Centessa Pharmaceuticals plc (NASDAQ:CNTA) Given Consensus Recommendation of "Moderate Buy" by Analysts americanbankingnews.com - November 22 at 3:40 AM
	Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know finance.yahoo.com - November 16 at 12:54 PM
	Jefferies Upgrades Centessa Pharmaceuticals plc - ADR (CNTA) msn.com - November 16 at 12:54 PM
	Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know finance.yahoo.com - November 16 at 12:54 PM
	Centessa Pharmaceuticals: Diversified Pipeline and Strong Financial Position Bolsters Buy Rating markets.businessinsider.com - November 16 at 1:25 AM
	Jefferies upgrades Centessa to buy, cites upcoming data for narcolepsy drug msn.com - November 15 at 8:25 PM
	Centessa Pharmaceuticals PLC Reports Q3 2023 Financial Results and Business Progress finance.yahoo.com - November 14 at 10:05 PM
	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023 finance.yahoo.com - November 13 at 8:57 PM
	Centessa Pharmaceuticals plc - ADR (CNTA) Price Target Increased by 9.09% to 9.79 msn.com - November 3 at 9:37 AM
	Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting finance.yahoo.com - November 2 at 12:40 PM
	Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors finance.yahoo.com - October 31 at 10:22 AM
	Hold Rating for Centessa Pharmaceuticals: Potential of ORX750 and Considerations for Future Development markets.businessinsider.com - October 28 at 12:50 AM
	Centessa Pharmaceuticals’ ORX750 Promises Potential Superiority: An In-depth Analysis of the Buy Recommendation markets.businessinsider.com - October 28 at 12:50 AM
	Morgan Stanley Upgrades Centessa Pharmaceuticals plc - ADR (CNTA) msn.com - October 26 at 11:23 PM
	Morgan Stanley impressed with Centessa's lead candidate data at World Sleep Congress msn.com - October 26 at 6:22 PM
	Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders finance.yahoo.com - October 25 at 2:46 PM
	Centessa Pharmaceuticals plc - ADR (CNTA) Price Target Increased by 7.75% to 8.98 msn.com - October 5 at 2:13 AM
	Centessa Pharmaceuticals plc's (NASDAQ:CNTA) 8.9% loss last week hit both individual investors who own 41% as well as institutions finance.yahoo.com - October 4 at 2:42 PM
	Centessa Pharmaceuticals plc (NASDAQ:CNTA) SVP Sells $235,774.36 in Stock marketbeat.com - September 22 at 5:35 PM
	Centessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest Update marketbeat.com - September 16 at 12:18 AM
	BVF Inc. IL Purchases 2,528,870 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) marketbeat.com - September 12 at 4:47 AM
	Centessa Pharmaceuticals plc - ADR (CNTA) Price Target Increased by 15.30% to 8.33 msn.com - September 1 at 12:22 PM
	Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference finance.yahoo.com - August 31 at 8:07 PM
	Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference finance.yahoo.com - August 31 at 8:07 PM
	Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress finance.yahoo.com - August 23 at 5:39 PM
	Centessa Pharmaceuticals: Pipeline Progresses As PRESent-2 Initiated msn.com - August 17 at 12:29 PM
	Guggenheim Maintains Centessa Pharmaceuticals plc - ADR (CNTA) Buy Recommendation msn.com - August 16 at 10:17 AM
	SVB Securities Maintains Centessa Pharmaceuticals plc - ADR (CNTA) Outperform Recommendation msn.com - August 16 at 10:17 AM
	Where Centessa Pharmaceuticals Stands With Analysts markets.businessinsider.com - August 15 at 6:07 PM
	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023 finance.yahoo.com - August 14 at 3:10 PM
	Centessa Pharmaceuticals plc (NASDAQ:CNTA) Given Average Rating of "Moderate Buy" by Brokerages marketbeat.com - August 14 at 4:28 AM
	Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors finance.yahoo.com - July 10 at 12:16 PM
	Centessa Pharmaceuticals plc - ADR (CNTA) Price Target Increased by 8.76% to 6.55 msn.com - July 6 at 11:00 PM
	Evercore ISI Group Initiates Coverage of Centessa Pharmaceuticals plc - ADR (CNTA) with Outperform Recommendation msn.com - June 22 at 8:01 AM
	Guggenheim Initiates Coverage of Centessa Pharmaceuticals plc - ADR (CNTA) with Buy Recommendation msn.com - June 13 at 4:33 AM
	Centessa Pharmaceuticals (NASDAQ:CNTA) Coverage Initiated by Analysts at Guggenheim marketbeat.com - June 12 at 10:19 AM
	Antoine Yver Sells 6,500 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock marketbeat.com - June 2 at 8:28 PM
	Centessa Pharmaceuticals plc (NASDAQ:CNTA) Given Average Rating of "Hold" by Brokerages marketbeat.com - May 31 at 3:34 AM
	Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $35,840.00 in Stock marketbeat.com - May 26 at 6:47 PM
	Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B finanznachrichten.de - May 23 at 9:14 PM
	Centessa Pharma Announces FDA's Decision To Grant Fast Track Designation For SerpinPC markets.businessinsider.com - May 22 at 8:10 AM
	Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B finance.yahoo.com - May 22 at 8:10 AM
	Centessa Pharmaceuticals: Highly Diversified With Decent Cash, Good Data, No Near-Term Catalysts seekingalpha.com - May 22 at 6:08 AM
	Goldman Sachs Maintains Centessa Pharmaceuticals plc - ADR (CNTA) Neutral Recommendation msn.com - May 15 at 7:58 PM
	Centessa Pharmaceuticals: Q1 Earnings Insights msn.com - May 12 at 10:20 AM
	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023 finance.yahoo.com - May 12 at 10:20 AM
	marketbeat.com - April 28 at 9:36 AM
	Centessa Pharmaceuticals plc (NASDAQ:CNTA) most popular amongst private equity firms who own 42% of the shares, institutions hold 22% finance.yahoo.com - April 27 at 3:31 PM
	Short Interest in Centessa Pharmaceuticals plc (NASDAQ:CNTA) Rises By 6.6% marketbeat.com - April 21 at 4:46 PM

Get Centessa Pharmaceuticals News Delivered to You Automatically

CNTA Media Mentions By Week

CNTA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CNTA
News Sentiment
▼
0.35

0.75
▲
Average
Medical
News Sentiment

CNTA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CNTA Articles
This Week
▼
3

1
▲
CNTA Articles
Average Week

Get Centessa Pharmaceuticals News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:CNTA) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Centessa Pharmaceuticals (CNTA) News Today

CNTA Media Mentions By Week

CNTA Media Sentiment

CNTA News Coverage

Related Companies and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info